Nikoletta L Kallinteris - JoVE Visualize

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2010

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancerSonia A Perez, Nikoletta L Kallinteris, Stratos Bisias, et al.

Cancer Immunology, Immunotherapy : CII|June 27, 2003

Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotypeXueqing Lu, Nikoletta L Kallinteris, Jizhi Li, et al.

Human Gene Therapy|March 12, 2005

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii proteinYu Wang, Minzhen Xu, Mingxin Che, et al.

Human Gene Therapy|June 14, 2003

Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinomaGilda G Hillman, Minzhen Xu, Yu Wang, et al.

Cancer Immunology, Immunotherapy : CII|September 9, 2006

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.

Cancer Treatment Reviews|April 3, 2004

Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidationGilda G Hillman, Nikoletta L Kallinteris, Xueqing Lu, et al.

Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2010

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancerSonia A Perez, Nikoletta L Kallinteris, Stratos Bisias, et al.

Cancer Immunology, Immunotherapy : CII|June 27, 2003

Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotypeXueqing Lu, Nikoletta L Kallinteris, Jizhi Li, et al.

Human Gene Therapy|March 12, 2005

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii proteinYu Wang, Minzhen Xu, Mingxin Che, et al.

Human Gene Therapy|June 14, 2003

Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinomaGilda G Hillman, Minzhen Xu, Yu Wang, et al.

Cancer Immunology, Immunotherapy : CII|September 9, 2006

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.

Cancer Treatment Reviews|April 3, 2004

Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidationGilda G Hillman, Nikoletta L Kallinteris, Xueqing Lu, et al.

Pageof 2